10-Q · May 13, 2026
Oruka Therapeutics reported substantial operating losses in Q1 2026, with a net loss of $31.8 million compared to a loss of $21 million in Q1 2025, marking a 52% increase. Cash and cash equivalents stood at $496…
Earnings analysis · 10-Q
ORKA earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Oruka reported Q2 diluted EPS of -$0.55 and $0.0 revenue, with losses worsening from both Q1 2026 and Q2 2025. The company materially improved its funding position through a $658.3 million April offering and $161.4…
Read full summary
Oruka reported Q2 diluted EPS of -$0.55 and $0.0 revenue, with losses worsening from both Q1 2026 and Q2 2025. The company materially improved its funding position through a $658.3 million April offering and $161.4 million of ATM net proceeds as of July 31, 2026, but this came with substantial dilution and does not change its lack of commercial revenue. Clinical development progressed across ORKA-001 and ORKA-002, including a new ORKA-002 Phase 2 hidradenitis suppurativa trial, while sole-source manufacturing, BIOSECURE Act exposure, regulatory uncertainty, and continued losses remain significant risks.
Reported figures
- Earnings per share
- $-0.55
What stood out
-
Losses Worsened With No Revenue
Q2 diluted EPS was -$0.55 versus -$0.48 in Q1 2026 and -$0.46 in Q2 2025, indicating sequential and year-over-year deterioration in losses. Revenue was $0.0, consistent with the company’s statement that it has never generated revenue from product sales.
-
Substantial Capital Raised
The company completed an April 2026 offering of 9,660,000 common shares for net proceeds of $658.3 million. It also generated $161.4 million of net proceeds from its ATM program as of July 31, 2026, materially strengthening available funding.
-
Clinical Programs Continue Advancing
ORKA-001 Phase 1 in healthy volunteers is fully enrolled and ongoing for follow-up, while its Phase 2a and Phase 2b psoriasis trials remain ongoing. ORKA-002 Phase 1 is also fully enrolled and ongoing, and a Phase 2 psoriasis trial began in February 2026.
-
ORKA-002 Expands Into HS
The company initiated a Phase 2 trial of ORKA-002 in hidradenitis suppurativa, expanding development beyond psoriasis and supporting the company’s focus on its two most advanced programs, ORKA-001 and ORKA-002.
-
Controls Remained Effective
Management concluded that disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
What to watch
-
Continued Financing and Dilution Risk
The company states that it will need to raise substantial additional capital and expects significant expenses and increasing operating losses for the foreseeable future. The April 2026 financing issued 9,660,000 shares, while the ATM program had produced $161.4 million of net proceeds as of July 31, 2026, highlighting both funding capacity and dilution risk.
-
Sole-Source and BIOSECURE Exposure
The company relies on a sole-source relationship for ORKA-001 and ORKA-002 manufacturing and currently relies on foreign CROs and CMOs, including WuXi Biologics. The filing states that designation under the BIOSECURE Act could require a provider transition, causing supply disruptions or higher costs.
-
Concentrated Clinical Risk
Development is concentrated in two advanced programs, ORKA-001 and ORKA-002. ORKA-001 has ongoing Phase 2a and Phase 2b psoriasis trials, while ORKA-002 began Phase 2 psoriasis development in February 2026 and recently entered Phase 2 hidradenitis suppurativa development; delays, safety issues, or inconclusive data could materially impair the pipeline.
-
Potential FDA Review Delays
The filing adds or emphasizes uncertainty from potential FDA disruption, noting mass federal-government layoffs since January 2025 and the possibility that reductions in FDA staffing or funding could lengthen review periods and delay clinical development.
-
No Commercial Revenue or Profit
The company has never generated revenue from product sales and states it may never become profitable. Q2 diluted EPS was -$0.55, compared with -$0.46 in Q2 2025, underscoring the ongoing operating-loss profile.
Management's outlook
No numeric revenue or EPS guidance was provided. Management states it expects to continue incurring significant expenses and increasing operating losses for the foreseeable future; development milestones remain subject to change.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.